Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.
You may also be interested in...
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Gilead Letairis Will Be Available Through LEAP Restricted Distribution Program
Ambrisentan beats out Encysive's Thelin in race for FDA approval for treatment of pulmonary arterial hypertension.
Actelion Will Take Novel Sleep Therapy Into Phase III This Year
The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.